Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc. Common Shares
(NY:
CYBN
)
9.410
-0.120 (-1.26%)
Streaming Delayed Price
Updated: 10:12 AM EST, Dec 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc. Common Shares
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
38
39
Next >
Psychedelic Stock Gainers And Losers From February 15, 2023
February 15, 2023
Via
Benzinga
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
February 14, 2023
Via
Benzinga
Cybin Reports Q3 Earnings, Says Psilocybin Tial Is Progressing As MDD Treatment
February 14, 2023
Cybin Inc. (NYSE: CYBN) has shared its unaudited financial results for the third quarter that ended Dec. 31, 2022. The company held total cash of $16.9 (CA$22.5) million as of Dec. 31, 2022, and $15...
Via
Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report, Corporate Highlights
February 14, 2023
Via
Investor Brand Network
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
February 14, 2023
From
Cybin Inc.
Via
Business Wire
Mind Medicine, GH Research Among Top Psychedelic Movers Of Today
February 13, 2023
Via
Benzinga
"Multi-Bagger" Portfolio Update
February 12, 2023
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022. I'm tracking 12 microcap stocks that might bounce back with major returns - dare I say
Via
Talk Markets
Major Psychedelic Compound-Based Stocks UP 13% YTD
February 11, 2023
We track the performance of the 6 largest companies researching the treatment of mental illnesses based on the use of one or more of 10 different psychedelic compound-based substances.
Via
Talk Markets
Cybin, Seelos Therapeutics Among Top Psychedelic Movers Of Today
February 10, 2023
Via
Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
February 09, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From February 8, 2023
February 08, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From February 7, 2023
February 07, 2023
Via
Benzinga
The "Multi-Bagger" Portfolio Continued To Outperform The S&P 500 Last Week
February 06, 2023
Our basket of mostly microcap cannabis, psychedelic and plant-based food stocks was extremely oversold in 2022 but we're watching for them to bounce back in 2023.
Via
Talk Markets
Mind Medicine, GH Research Among Top Psychedelic Movers Of Today
February 06, 2023
Via
Benzinga
The 7 Most Promising Psychedelic Stocks to Buy in February
February 05, 2023
These psychedelics stocks to buy belong to pre-revenue firms which could potentially blow-up in line with the burgeoning sector.
Via
InvestorPlace
6 Largest Psychedelic Stocks Down 3% This Week
February 04, 2023
The six largest of the 40 companies researching the treatment of mental illnesses by using psychedelic substances, which constitute our Psychedelic Drug Stocks Index, are now up 13% YTD despite a loss...
Via
Talk Markets
Psychedelic Stock Gainers And Losers From February 3, 2023
February 03, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From February 2, 2023
February 02, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From February 1, 2023
February 01, 2023
Via
Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule
February 01, 2023
Via
Investor Brand Network
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment
February 01, 2023
Cybin Inc. (NYSE: CYBN) announced that it has received approval from an independent ethics committee in the Netherlands to begin the first in-human dosing of its proprietary deuterated...
Via
Benzinga
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
February 01, 2023
From
Cybin Inc.
Via
Business Wire
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
January 31, 2023
Via
Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
January 30, 2023
Via
Benzinga
The "Multi-Bagger" Portfolio Update: Week Ending January 27
January 29, 2023
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022 but many of them could possibly bounce back with major returns in 2023. We track the performance of a basket of 10 such...
Via
Talk Markets
Largest Psychedelic Stocks +1.2% This Week; Now +16.1% YTD
January 28, 2023
We track the 6 largest psychedelic stocks that research the treatment of mental illnesses based on the use of one or more psychedelic substances - weekly and YTD results.
Via
Talk Markets
Cybin, GH Research Among Top Psychedelic Movers Of Today
January 27, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 26, 2023
January 26, 2023
Via
Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day
January 26, 2023
Via
Investor Brand Network
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
January 26, 2023
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Economy
Exposures
Supply Chain
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
38
39
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
